← 產業報告目錄

Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Packaging出版日期 2025-03-12頁數 522報告編號 PH1622

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global clinical trial services market is projected to reach USD 101.86 billion in 2030 from USD 66.59 billion in 2025, growing at a CAGR of 8.9% during the forecast period. This market is expanding as pharmaceutical, biotechnology, and medical device companies are increasingly outsourcing their clinical research activities to Contract Research Organizations (CROs). Flexible service models, such as Functional Service Provider (FSP) and hybrid service delivery models, offered by CROs enable cost management while allowing companies to retain control over critical operations. There is a growing demand for patient-centric trials, leveraging decentralized models, wearable devices, and digital platforms to enhance patient participation and retention. Technological advancements, including artificial intelligence (AI) and real-world data (RWD), are optimizing trial efficiency, site selection, and patient recruitment. The rising demand for personalized and precision medicine is driving an increase in clinical studies focused on targeted therapies, requiring CROs to support complex trial designs. Regulatory bodies are emphasizing pediatric clinical trials, requiring CROs to develop specialized expertise. Additionally, FDA guidelines promoting diversity in clinical trials are creating opportunities for CROs to expand patient recruitment and ensure broader representation. The increasing pipeline of new drug modalities, including cell and gene therapies, biologics, and RNA-based treatments, is further driving the need for specialized clinical research services. “The oncology therapy area segment held the largest share in the clinical trial services market, by therapy area, during the forecast period” In 2024, the oncology therapy area held the largest market within the clinical trial services market by therapy area. Factors such as the large number of cancer cases worldwide and the need for new treatments are supporting the large share of this therapy area. Cancer research is complex, requiring trials for targeted therapies, immunotherapies, and combination treatments. Regulatory agencies prioritize cancer drug approvals, leading to more trials in this area. Advances in precision medicine and biomarker research have also increased oncology trials, requiring expertise in patient recruitment and trial management. Strong investments from pharmaceutical companies, government agencies, and patient organizations further drive cancer research, making oncology the leading segment in clinical trials. “The pharmaceutical & biopharmaceutical companies end user segment held the largest market share in the clinical trials services market, by end user, during the forecast period” Pharmaceutical and biopharmaceutical companies dominated the clinical trial services end-user/sponsor market during the forecast period. Conducting in-house trials demands substantial investments in infrastructure, personnel, and regulatory compliance, making outsourcing a more cost-effective and efficient alternative as trial complexity increases. Partnering with Contract Research Organizations (CROs) allows these companies to leverage expertise in trial design, patient recruitment, regulatory adherence, and data management, expediting drug development. Additionally, the expanding R&D pipeline and growing focus on precision medicine have led pharmaceutical companies to outsource clinical services and laboratory testing, minimizing operational burdens and optimizing resources. “Asia Pacific: The fastest growing region in the clinical trial services market” The Asia Pacific clinical trial services market is projected to register the highest growth rate during the forecast period. This high growth is attributed to its large patient pool, high incidence of chronic and infectious diseases, and growing focus on developing biologics, biosimilars, and advanced therapies. Global pharmaceutical companies are increasingly shifting manufacturing and clinical research to the region to benefit from cost advantages, regulatory improvements, and better patient retention in trials. Additionally, government support and increasing investments in clinical research have further driven the outsourcing of clinical trial activities to APAC, contributing to its strong market growth. The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 – 44%, Tier 2 – 32%, and Tier 3 – 24% • By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25% • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15% List of Companies Profiled in the Report: • IQVIA Inc. (US) • Thermo Fisher Scientific Inc. (US) • Fortrea (US) • ICON Plc (Ireland) • Syneos Health (US) • Laboratory Corporation of America Holdings (US) • Medpace (US) • Wuxi AppTec (China) • Frontage Labs (US) • Pharmaron (US) • Tigermed (China) • SGS Société Générale De Surveillance SA. (Switzerland) • Eurofins Scientific (Luxembourg) • Linical (Japan) • Parexel International Corporation (US) • Worldwide Clinical Trials (US) • Novotech (Australia) • PSI (Switzerland) • Allucent (US) • Premier Research (US) • Clario (US) • KCR S.A. (US) • Rho, Inc. (US) • Advanced Clinical (US) Research Coverage: This report provides a detailed picture of the global clinical trial service market. It aims to estimate the size and future growth potential of the market across different segments such as the service type, therapy area, phase, delivery model, modality, end user/sponsor, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial services market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new service launches, mergers and acquisitions, and recent developments associated with the clinical trial services market. Competitive analysis of upcoming startups in the clinical trial services market ecosystem is covered in this report. Reasons to buy this report : The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall clinical trial services market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. The report provides insights on the following pointers: • Analysis of key drivers (Increasing focus on patient-centric trials (DCTs), increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing, rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities, service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid) and technological integrations), opportunities (Increased focus on pediatric clinical trials, regulatory requirement for increasing diversity in clinical trials, growing role of real-world evidence in drug approvals, expanding drug modalities (such as CGT, ADCs, Bispecific Abs) in clinical trials), and challenges (Cybersecurity or intellectual property concerns, and challenge of patient retention) influencing the growth of the clinical trial services market. • Service Development/Innovation: Detailed insights on upcoming technologies, and new service launches in the clinical trial services market • Market Development: Comprehensive information about lucrative markets – the report analyses the clinical trial services market across varied regions. • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trial services market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the clinical trial services market
目錄 Table of Contents
1 INTRODUCTION 45 1.1 STUDY OBJECTIVES 45 1.2 MARKET DEFINITION 45 1.3 STUDY SCOPE 46 1.3.1 MARKETS COVERED 46 1.3.2 REGIONAL SCOPE 47 1.3.3 INCLUSIONS AND EXCLUSIONS 47 1.3.4 YEARS CONSIDERED 49 1.4 CURRENCY CONSIDERED 49 1.5 STAKEHOLDERS 49 1.6 SUMMARY OF CHANGES 50 2 RESEARCH METHODOLOGY 51 2.1 RESEARCH DATA 51 2.1.1 SECONDARY DATA 52 2.1.2 PRIMARY DATA 52 2.2 GLOBAL MARKET ESTIMATION 53 2.2.1 MARKET ESTIMATION METHODOLOGY 53 2.2.1.1 Insights from primary experts 56 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 57 2.3 MARKET GROWTH RATE PROJECTION 58 2.4 DATA TRIANGULATION 60 2.5 RESEARCH ASSUMPTIONS 61 2.6 RESEARCH LIMITATIONS 62 3 EXECUTIVE SUMMARY 63 4 PREMIUM INSIGHTS 68 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CLINICAL TRIAL SERVICES MARKET 68 4.2 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND COUNTRY (2024) 69 4.3 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE (2025 VS. 2030) 69 4.4 CLINICAL TRIAL SERVICES MARKET, BY END USER (2024) 70 4.5 CLINICAL TRIAL SERVICES MARKET, BY COUNTRY 70   5 MARKET OVERVIEW 71 5.1 INTRODUCTION 71 5.2 MARKET DYNAMICS 71 5.2.1 DRIVERS 72 5.2.1.1 Increasing focus on patient-centric trials (DCTs) 72 5.2.1.2 Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing 73 5.2.1.3 Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities 74 5.2.1.4 Service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid) 75 5.2.1.5 Technological integrations 76 5.2.2 OPPORTUNITIES 76 5.2.2.1 Increased focus on pediatric clinical trials 76 5.2.2.2 Increasing regulatory requirements for increasing diversity in clinical trials 77 5.2.2.3 Growing role of real-world evidence in drug approvals 78 5.2.2.4 Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials 79 5.2.3 CHALLENGES 80 5.2.3.1 Cybersecurity or intellectual property concerns 80 5.2.3.2 Challenge of patient retention 80 5.2.3.3 Growing market competition 81 5.3 MARKET TRENDS 81 5.3.1 IN SILICO CLINICAL TRIALS 81 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 81 5.5 PRICING ANALYSIS 82 5.5.1 PRICING ANALYSIS, BY KEY PLAYER (QUALITATIVE) 82 5.5.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2024 83 5.5.3 INDICATIVE PRICING ANALYSIS, BY THERAPEUTIC AREA, 2024 84 5.6 VALUE CHAIN ANALYSIS 84 5.7 ECOSYSTEM ANALYSIS 86 5.8 INVESTMENT AND FUNDING SCENARIO 88 5.9 TECHNOLOGY ANALYSIS 89 5.9.1 KEY TECHNOLOGIES 89 5.9.1.1 Clinical trial management system (CTMS) 89 5.9.1.2 Electronic data capture (EDC) systems 89 5.9.1.3 Randomization and trial supply management (RTSM) 90 5.9.2 COMPLEMENTARY TECHNOLOGIES 91 5.9.2.1 Telemedicine and wearable devices 91 5.9.2.2 AI and ML integration 91 5.10 KEY CONFERENCES AND EVENTS, 2025–2026 92   5.11 REGULATORY LANDSCAPE 93 5.11.1 REGULATORY FRAMEWORK 93 5.11.1.1 North America 93 5.11.1.2 Europe 94 5.11.1.3 Asia Pacific 94 5.11.1.4 RoW 95 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 5.12 PORTER’S FIVE FORCES ANALYSIS 103 5.12.1 THREAT OF NEW ENTRANTS 104 5.12.2 THREAT OF SUBSTITUTES 105 5.12.3 BARGAINING POWER OF SUPPLIERS 105 5.12.4 BARGAINING POWER OF BUYERS 105 5.12.5 INTENSITY OF COMPETITIVE RIVALRY 105 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 106 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 106 5.13.2 BUYING CRITERIA 107 5.14 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET 109 5.14.1 INTRODUCTION 109 5.14.2 MARKET POTENTIAL FOR CLINICAL TRIALS 109 5.14.3 AI USE CASES 110 5.14.4 KEY COMPANIES IMPLEMENTING AI 111 5.14.5 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM 111 6 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE 112 6.1 INTRODUCTION 113 6.2 CLINICAL TRIAL MANAGEMENT & MONITORING 114 6.2.1 RISING ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH 114 6.3 LABORATORY SERVICES 117 6.3.1 ANALYTICAL TESTING SERVICES 121 6.3.1.1 Increasing demand for analytical testing for drug development to drive market 121 6.3.2 BIOANALYTICAL TESTING SERVICES 124 6.3.2.1 Rising focus on biologics in advanced therapies to drive market 124 6.4 CLINICAL TRIAL DATA MANAGEMENT SERVICES 127 6.4.1 BIOSTATISTICS 131 6.4.1.1 Integration of real-world data (RWD) into statistical analysis to support market growth 131 6.4.2 OTHER DATA MANAGEMENT SERVICES 134   6.5 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES 137 6.5.1 COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET 137 6.6 CONSULTING 140 6.6.1 INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET 140 6.7 PATIENT RECRUITMENT & RETENTION 143 6.7.1 INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH 143 6.8 MEDICAL WRITING 145 6.8.1 INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET 145 6.9 SAFETY & PHARMACOVIGILANCE 148 6.9.1 REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH 148 6.10 OTHER SERVICE TYPES 151 7 CLINICAL TRIAL SERVICES MARKET, BY PHASE 154 7.1 INTRODUCTION 155 7.2 PHASE III 156 7.2.1 HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING 156 7.3 PHASE II 159 7.3.1 LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS 159 7.4 PHASE I 162 7.4.1 DECLINING TRIALS TO POSE CHALLENGE IN MARKET GROWTH 162 7.5 PHASE IV 166 7.5.1 SIGNIFICANCE OF PHASE IV FROM REGULATORY VIEWPOINT TO SUPPORT MARKET GROWTH 166 8 CLINICAL TRIAL SERVICES MARKET, BY MODALITY 169 8.1 INTRODUCTION 170 8.2 SMALL MOLECULES 170 8.2.1 EXTENSIVE PIPELINE OF DRUGS IN DEVELOPMENT PHASE AND GROWING INVESTMENTS IN R&D OF SMALL MOLECULES TO BOOST MARKET GROWTH 170 8.3 BIOLOGICS 174 8.3.1 GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND RISING REGULATORY SUPPORT TO PROPEL DEMAND 174 8.4 MEDICAL DEVICES & IVD 177 8.4.1 SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND 177 9 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA 180 9.1 INTRODUCTION 181 9.2 ONCOLOGY 182 9.2.1 GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET 182 9.3 NEUROLOGY 187 9.3.1 INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET 187 9.4 RESPIRATORY DISORDERS 190 9.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH 190 9.5 METABOLIC DISORDERS/ENDOCRINOLOGY 193 9.5.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH 193 9.6 CARDIOVASCULAR SYSTEM DISORDERS 197 9.6.1 HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET 197 9.7 DERMATOLOGY 200 9.7.1 GROWING FOCUS ON DRUG DEVELOPMENT FOR VARIOUS SKIN CONDITIONS TO SUPPORT MARKET GROWTH 200 9.8 GASTROINTESTINAL DISEASES 203 9.8.1 EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET 203 9.9 IMMUNOLOGICAL DISORDERS 206 9.9.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET GROWTH 206 9.10 INFECTIOUS DISEASES 209 9.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET 209 9.11 PSYCHIATRY 212 9.11.1 GROWING INCIDENCE OF PSYCHIATRIC DISORDERS TO SUPPORT MARKET GROWTH 212 9.12 OPHTHALMOLOGY 215 9.12.1 RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH 215 9.13 HEMATOLOGY 218 9.13.1 CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH 218 9.14 GENITOURINARY & WOMEN’S HEALTH 221 9.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET 221 9.15 OTHER THERAPEUTIC AREAS 224 10 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL 228 10.1 INTRODUCTION 229 10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL 229 10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 229 10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL 233 10.3.1 GROWING ADOPTION OF FSP SERVICE BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH 233   10.4 HYBRID MODEL 236 10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH 236 11 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN 239 11.1 INTRODUCTION 240 11.2 INTERVENTIONAL 240 11.2.1 MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET 240 11.3 OBSERVATIONAL 244 11.3.1 INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH 244 12 CLINICAL TRIAL SERVICES MARKET, BY END USER 247 12.1 INTRODUCTION 248 12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 248 12.2.1 INCREASE IN R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 248 12.3 MEDICAL DEVICE COMPANIES 253 12.3.1 RISING ACQUISITIONS AND EXPANSIONS OF SERVICE PORTFOLIOS BY MEDICAL DEVICE CRO SERVICE PROVIDERS TO DRIVE MARKET 253 12.4 ACADEMIC INSTITUTES 256 12.4.1 RISING COLLABORATIONS BETWEEN CROS AND ACADEMIA TO DRIVE MARKET 256 13 CLINICAL TRIAL SERVICES MARKET, BY REGION 259 13.1 INTRODUCTION 260 13.2 NORTH AMERICA 260 13.2.1 US 266 13.2.1.1 Presence of well-established CROs to drive market 266 13.2.2 CANADA 271 13.2.2.1 Favorable government-led initiatives and rising R&D investments to drive market 271 13.3 EUROPE 276 13.3.1 GERMANY 281 13.3.1.1 Growing R&D spending and favorable government policies to propel market 281 13.3.2 UK 286 13.3.2.1 Rising collaborations and improved policies to support market 286 13.3.3 FRANCE 291 13.3.3.1 Government-led support for effective drug research to drive market 291 13.3.4 ITALY 296 13.3.4.1 Government-led focus on improving clinical trial regulations to drive market 296 13.3.5 SPAIN 300 13.3.5.1 Rising R&D expenditure to boost market growth 300 13.3.6 REST OF EUROPE 304 13.4 ASIA PACIFIC 309 13.4.1 CHINA 315 13.4.1.1 Low manufacturing cost and increased establishment of R&D centers to drive market 315 13.4.2 INDIA 320 13.4.2.1 Cost-efficient and innovation-driven approach to propel market 320 13.4.3 JAPAN 325 13.4.3.1 Decline in number of clinical trials to limit market 325 13.4.4 AUSTRALIA 330 13.4.4.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market 330 13.4.5 SOUTH KOREA 335 13.4.5.1 Favorable government initiatives for drug development to drive market 335 13.4.6 REST OF ASIA PACIFIC 340 13.5 LATIN AMERICA 344 13.5.1 BRAZIL 348 13.5.1.1 Government-led support through improved policies in pharmaceutical R&D to drive market 348 13.5.2 MEXICO 353 13.5.2.1 Increasing investments in pharma R&D to drive market 353 13.5.3 REST OF LATIN AMERICA 356 13.6 MIDDLE EAST 361 13.6.1 GCC COUNTRIES 365 13.6.1.1 Saudi Arabia 369 13.6.1.1.1 Increase in collaborations to drive market 369 13.6.1.2 UAE 374 13.6.1.2.1 Growing clinical research activities to drive market 374 13.6.1.3 Rest of GCC countries 377 13.6.2 REST OF MIDDLE EAST 382 13.6.3 AFRICA 386 13.6.3.1 Expanding pharmaceutical industry to support market growth 386 14 COMPETITIVE LANDSCAPE 390 14.1 OVERVIEW 390 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 390 14.3 REVENUE ANALYSIS 393 14.4 MARKET SHARE ANALYSIS, 2024 394 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 396   14.5.1 STARS 396 14.5.2 EMERGING LEADERS 396 14.5.3 PERVASIVE PLAYERS 397 14.5.4 PARTICIPANTS 397 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 398 14.5.5.1 Company footprint 398 14.5.5.2 Region footprint 399 14.5.5.3 Service type footprint 400 14.5.5.4 Phase footprint 401 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 402 14.6.1 PROGRESSIVE COMPANIES 402 14.6.2 RESPONSIVE COMPANIES 402 14.6.3 DYNAMIC COMPANIES 402 14.6.4 STARTING BLOCKS 403 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 404 14.6.5.1 Detailed list of key startups/SMEs 404 14.6.5.2 Competitive benchmarking of startups/SMEs 405 14.7 COMPANY VALUATION AND FINANCIAL METRICS 406 14.8 BRAND/SERVICE COMPARISON 407 14.9 COMPETITIVE SCENARIO 408 14.9.1 SERVICE LAUNCHES 408 14.9.2 DEALS 409 14.9.3 EXPANSIONS 410 15 COMPANY PROFILES 411 15.1 KEY PLAYERS 411 15.1.1 IQVIA INC. 411 15.1.1.1 Business overview 411 15.1.1.2 Services offered 412 15.1.1.3 Recent developments 414 15.1.1.3.1 Service launches 414 15.1.1.3.2 Deals 414 15.1.1.3.3 Expansions 416 15.1.1.4 MnM view 417 15.1.1.4.1 Right to win 417 15.1.1.4.2 Strategic choices 417 15.1.1.4.3 Weaknesses and competitive threats 417 15.1.2 ICON PLC 418 15.1.2.1 Business overview 418 15.1.2.2 Services offered 419 15.1.2.3 Recent developments 426 15.1.2.3.1 Service launches 426 15.1.2.3.2 Deals 426 15.1.2.4 MnM view 427 15.1.2.4.1 Right to win 427 15.1.2.4.2 Strategic choices 427 15.1.2.4.3 Weaknesses and competitive threats 427 15.1.3 THERMO FISHER SCIENTIFIC INC. 428 15.1.3.1 Business overview 428 15.1.3.2 Services offered 429 15.1.3.3 Recent developments 435 15.1.3.3.1 Service launches 435 15.1.3.3.2 Deals 435 15.1.3.3.3 Expansions 437 15.1.3.4 MnM view 438 15.1.3.4.1 Right to win 438 15.1.3.4.2 Strategic choices 438 15.1.3.4.3 Weaknesses and competitive threats 438 15.1.4 FORTREA 439 15.1.4.1 Business overview 439 15.1.4.2 Services offered 440 15.1.4.3 Recent developments 444 15.1.4.3.1 Service launches 444 15.1.4.3.2 Deals 444 15.1.4.3.3 Expansions 445 15.1.4.4 MnM view 445 15.1.4.4.1 Right to win 445 15.1.4.4.2 Strategic choices 445 15.1.4.4.3 Weaknesses and competitive threats 445 15.1.5 SYNEOS HEALTH 446 15.1.5.1 Business overview 446 15.1.5.2 Services offered 447 15.1.5.3 Recent developments 448 15.1.5.3.1 Service launches 448 15.1.5.3.2 Deals 448 15.1.5.4 MnM view 451 15.1.5.4.1 Right to win 451 15.1.5.4.2 Strategic choices 451 15.1.5.4.3 Weaknesses and competitive threats 452 15.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 453 15.1.6.1 Business overview 453 15.1.6.2 Services offered 455 15.1.6.3 Recent developments 456 15.1.6.3.1 Service launches 456 15.1.6.3.2 Deals 456 15.1.6.3.3 Expansions 457 15.1.6.4 MnM view 458 15.1.6.4.1 Right to win 458 15.1.6.4.2 Strategic choices 458 15.1.6.4.3 Weaknesses and competitive threats 458 15.1.7 MEDPACE 459 15.1.7.1 Business overview 459 15.1.7.2 Services offered 460 15.1.8 WUXI APPTEC 463 15.1.8.1 Business overview 463 15.1.8.2 Services offered 464 15.1.8.3 Recent developments 467 15.1.8.3.1 Deals 467 15.1.9 FRONTAGE LABS 468 15.1.9.1 Business overview 468 15.1.9.2 Services offered 469 15.1.9.3 Recent developments 470 15.1.9.3.1 Deals 470 15.1.9.3.2 Expansions 471 15.1.10 PHARMARON 472 15.1.10.1 Business overview 472 15.1.10.2 Services offered 474 15.1.11 TIGERMED 475 15.1.11.1 Business overview 475 15.1.11.2 Services offered 476 15.1.11.3 Recent developments 478 15.1.11.3.1 Service approvals 478 15.1.11.3.2 Deals 479 15.1.12 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA 480 15.1.12.1 Business overview 480 15.1.12.2 Services offered 482 15.1.13 EUROFINS SCIENTIFIC 483 15.1.13.1 Business overview 483 15.1.13.2 Services offered 485 15.1.14 LINICAL 486 15.1.14.1 Business overview 486 15.1.14.2 Services offered 488 15.1.14.3 Recent developments 488 15.1.14.3.1 Deals 488 15.1.14.3.2 Expansions 489   15.1.15 PAREXEL INTERNATIONAL CORPORATION 490 15.1.15.1 Business overview 490 15.1.15.2 Services offered 491 15.1.15.3 Recent developments 492 15.1.15.3.1 Service launches 492 15.1.15.3.2 Deals 492 15.1.15.3.3 Expansions 494 15.2 OTHER PLAYERS 495 15.2.1 WORLDWIDE CLINICAL TRIALS 495 15.2.2 PROPHARMA 497 15.2.3 NOVOTECH 498 15.2.4 PSI 501 15.2.5 ALLUCENT 502 15.2.6 PREMIER RESEARCH 503 15.2.7 CAIDYA 504 15.2.8 ERGOMED GROUP 505 15.2.9 CLARIO 507 15.2.10 PRECISION MEDICINE GROUP, LLC. 508 15.2.11 ADVANCED CLINICAL 509 15.2.12 EPS HOLDINGS, INC. 510 15.2.13 GUIRES INC. (PEPGRA) 511 15.2.14 KCR S.A. 512 16 APPENDIX 513 16.1 DISCUSSION GUIDE 513 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 518 16.3 CUSTOMIZATION OPTIONS 520 16.4 RELATED REPORTS 520 16.5 AUTHOR DETAILS 521
圖表清單 List of Tables & Figures
TABLE 1 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 59 TABLE 2 RISK ASSESSMENT 62 TABLE 3 CLINICAL TRIAL SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 72 TABLE 4 INDICATIVE PRICING ANALYSIS OF CLINICAL TRIAL SERVICES, BY PHASE, 2024 (USD) 83 TABLE 5 INDICATIVE PRICING ANALYSIS OF CLINICAL TRIAL SERVICES, BY THERAPEUTIC AREA, 2024 (USD) 84 TABLE 6 CLINICAL TRIAL SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 87 TABLE 7 CLINICAL TRIAL SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 92 TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 13 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES 100 TABLE 14 CLINICAL TRIAL SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 103 TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES FOR END USER 106 TABLE 16 BUYING CRITERIA FOR CLINICAL TRIAL SERVICES, BY END USER 108 TABLE 17 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 113 TABLE 18 CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 19 NORTH AMERICA: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 20 EUROPE: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 21 ASIA PACIFIC: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 22 LATIN AMERICA: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 23 MIDDLE EAST: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 24 GCC COUNTRIES: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 25 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 118 TABLE 26 LABORATORY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 27 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 28 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 29 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 30 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 31 MIDDLE EAST: LABORATORY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 32 GCC COUNTRIES: LABORATORY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 33 LABORATORY SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 121 TABLE 34 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 35 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 36 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 37 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 38 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 39 MIDDLE EAST: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 40 GCC COUNTRIES: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 41 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 42 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 43 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 44 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 45 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 46 MIDDLE EAST: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 47 GCC COUNTRIES: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 48 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 127 TABLE 49 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 50 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 51 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 52 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 53 LATIN AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 54 MIDDLE EAST: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 55 GCC COUNTRIES: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 56 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 131 TABLE 57 CLINICAL TRIAL DATA MANAGEMENT SERVICES: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 58 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 59 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 60 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 61 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 62 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 63 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 64 OTHER DATA MANAGEMENT SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 65 NORTH AMERICA: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 66 EUROPE: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 67 ASIA PACIFIC: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 68 LATIN AMERICA: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 69 MIDDLE EAST: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 70 GCC COUNTRIES: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 71 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 72 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 73 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 74 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 75 LATIN AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 76 MIDDLE EAST: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 77 GCC COUNTRIES: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 78 CONSULTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 79 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 80 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 81 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 82 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 83 MIDDLE EAST: CONSULTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 84 GCC COUNTRIES: CONSULTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 85 PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 86 NORTH AMERICA: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 87 EUROPE: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 88 ASIA PACIFIC: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION), BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 89 LATIN AMERICA: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 90 MIDDLE EAST: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 91 GCC COUNTRIES: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 92 MEDICAL WRITING SERVICE MARKET, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 93 NORTH AMERICA: MEDICAL WRITING SERVICE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 94 EUROPE: MEDICAL WRITING SERVICE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 95 ASIA PACIFIC: MEDICAL WRITING SERVICE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 96 LATIN AMERICA: MEDICAL WRITING SERVICE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 97 MIDDLE EAST: MEDICAL WRITING SERVICE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 98 GCC COUNTRIES: MEDICAL WRITING SERVICE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 99 SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 100 NORTH AMERICA: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 101 EUROPE: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 102 ASIA PACIFIC: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 103 LATIN AMERICA: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 104 MIDDLE EAST: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 105 GCC COUNTRIES: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 106 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 107 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 108 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 109 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 110 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LATIN AMERICA, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 111 MIDDLE EAST: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 112 GCC COUNTRIES: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 113 CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 155 TABLE 114 CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 115 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 116 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 117 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 118 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 119 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 120 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 121 CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 122 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 123 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 124 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 125 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 126 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 127 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 128 CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 129 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 130 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 131 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 132 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 133 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 134 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 135 CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 136 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 137 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 138 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 139 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 140 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 141 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 142 CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 170 TABLE 143 CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 144 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 145 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 146 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 147 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 148 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 149 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 150 CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 151 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 152 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 153 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 154 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 155 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 156 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 157 CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY REGION, 2023–2030 (USD MILLION) 177 TABLE 158 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 159 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 160 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 161 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 162 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 163 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 164 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 181 TABLE 165 NUMBER OF NEW CANCER CASES, BY TYPE, 2022 VS. 2040 182 TABLE 166 CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 167 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 168 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 169 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 170 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 171 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 172 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 173 CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 174 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 175 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 176 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 177 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 178 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 179 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 180 CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 181 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 182 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 183 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 184 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 185 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 186 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 187 CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 188 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 189 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 190 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 191 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 192 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 193 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 194 CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 195 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 196 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 197 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 198 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 199 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 200 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 201 CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 202 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 203 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 204 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 205 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 206 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 207 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 208 CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 209 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 210 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 211 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 212 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 213 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 214 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 215 CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 207 TABLE 216 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 217 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 218 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 219 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 220 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 221 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 222 CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 223 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 224 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 225 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 226 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 227 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 228 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 229 CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2023–2030 (USD MILLION) 213 TABLE 230 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 231 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 232 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 233 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 234 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 235 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 236 CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2023–2030 (USD MILLION) 216 TABLE 237 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 238 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 239 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 240 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 241 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 242 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 243 CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2023–2030 (USD MILLION) 219 TABLE 244 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 245 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 246 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 247 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 248 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 249 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 250 CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION) 222 TABLE 251 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 252 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 253 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 254 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 255 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 256 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 224 TABLE 257 CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 225 TABLE 258 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 259 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 260 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 261 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 262 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 263 OTHER THERAPEUTIC AREAS: CLINICAL TRIAL SERVICES MARKET FOR GCC COUNTRIES, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 264 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 229 TABLE 265 CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY REGION, 2023–2030 (USD MILLION) 230 TABLE 266 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 230 TABLE 267 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 268 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 269 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 232 TABLE 270 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 232 TABLE 271 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 232 TABLE 272 CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY REGION, 2023–2030 (USD MILLION) 233 TABLE 273 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 234 TABLE 274 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 234 TABLE 275 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 234 TABLE 276 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 277 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 278 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 279 CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY REGION, 2023–2030 (USD MILLION) 236 TABLE 280 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 236 TABLE 281 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 282 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 283 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 284 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 238 TABLE 285 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 238 TABLE 286 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 240 TABLE 287 CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY REGION, 2023–2030 (USD MILLION) 241 TABLE 288 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 241 TABLE 289 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 242 TABLE 290 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 242 TABLE 291 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 243 TABLE 292 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 243 TABLE 293 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 243 TABLE 294 CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY REGION, 2023–2030 (USD MILLION) 244 TABLE 295 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 296 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 297 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 298 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 246 TABLE 299 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 246 TABLE 300 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 246 TABLE 301 CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 248 TABLE 302 CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION) 250 TABLE 303 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 250 TABLE 304 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 251 TABLE 305 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 251 TABLE 306 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 252 TABLE 307 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 252 TABLE 308 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 252 TABLE 309 CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2023–2030 (USD MILLION) 253 TABLE 310 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 254 TABLE 311 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 254 TABLE 312 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 254 TABLE 313 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 255 TABLE 314 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 255 TABLE 315 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 255 TABLE 316 CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 256 TABLE 317 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 256 TABLE 318 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 257 TABLE 319 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 257 TABLE 320 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 257 TABLE 321 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 258 TABLE 322 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 258 TABLE 323 CLINICAL TRIAL SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 260 TABLE 324 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 262 TABLE 325 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 262 TABLE 326 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 263 TABLE 327 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 263 TABLE 328 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 263 TABLE 329 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 264 TABLE 330 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 265 TABLE 331 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 265 TABLE 332 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 265 TABLE 333 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 266 TABLE 334 US: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 267 TABLE 335 US: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 267 TABLE 336 US: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 268 TABLE 337 US: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 268 TABLE 338 US: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 269 TABLE 339 US: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 269 TABLE 340 US: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 270 TABLE 341 US: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 270 TABLE 342 US: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 270 TABLE 343 CANADA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 272 TABLE 344 CANADA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 272 TABLE 345 CANADA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 273 TABLE 346 CANADA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 273 TABLE 347 CANADA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 274 TABLE 348 CANADA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 274 TABLE 349 CANADA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 275 TABLE 350 CANADA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 275 TABLE 351 CANADA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 275 TABLE 352 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 276 TABLE 353 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 277 TABLE 354 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 277 TABLE 355 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 278 TABLE 356 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 278 TABLE 357 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 279 TABLE 358 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 279 TABLE 359 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 280 TABLE 360 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 280 TABLE 361 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 362 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 282 TABLE 363 GERMANY: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 282 TABLE 364 GERMANY: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 283 TABLE 365 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 283 TABLE 366 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 284 TABLE 367 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 284 TABLE 368 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 285 TABLE 369 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 285 TABLE 370 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 285 TABLE 371 UK: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 287 TABLE 372 UK: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 287 TABLE 373 UK: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 288 TABLE 374 UK: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 288 TABLE 375 UK: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 289 TABLE 376 UK: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 289 TABLE 377 UK: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 290 TABLE 378 UK: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 290 TABLE 379 UK: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 290 TABLE 380 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 292 TABLE 381 FRANCE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 292 TABLE 382 FRANCE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 293 TABLE 383 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 293 TABLE 384 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 294 TABLE 385 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 294 TABLE 386 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 295 TABLE 387 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 295 TABLE 388 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 295 TABLE 389 ITALY: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 296 TABLE 390 ITALY: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 297 TABLE 391 ITALY: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 297 TABLE 392 ITALY: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 297 TABLE 393 ITALY: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 298 TABLE 394 ITALY: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 298 TABLE 395 ITALY: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 299 TABLE 396 ITALY: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 299 TABLE 397 ITALY: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 299 TABLE 398 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 300 TABLE 399 SPAIN: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 301 TABLE 400 SPAIN: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 301 TABLE 401 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 301 TABLE 402 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 302 TABLE 403 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 302 TABLE 404 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 303 TABLE 405 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 303 TABLE 406 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 303 TABLE 407 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 305 TABLE 408 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 305 TABLE 409 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 306 TABLE 410 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 306 TABLE 411 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 307 TABLE 412 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 307 TABLE 413 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 308 TABLE 414 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 308 TABLE 415 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 308 TABLE 416 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 311 TABLE 417 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 311 TABLE 418 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 312 TABLE 419 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 312 TABLE 420 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 313 TABLE 421 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 313 TABLE 422 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 314 TABLE 423 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 314 TABLE 424 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 314 TABLE 425 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 315 TABLE 426 CHINA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 316 TABLE 427 CHINA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 317 TABLE 428 CHINA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 317 TABLE 429 CHINA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 317 TABLE 430 CHINA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 318 TABLE 431 CHINA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 318 TABLE 432 CHINA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 319 TABLE 433 CHINA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 319 TABLE 434 CHINA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 319 TABLE 435 INDIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 321 TABLE 436 INDIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 321 TABLE 437 INDIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 322 TABLE 438 INDIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 322 TABLE 439 INDIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 323 TABLE 440 INDIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 323 TABLE 441 INDIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 324 TABLE 442 INDIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 324 TABLE 443 INDIA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 324 TABLE 444 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 326 TABLE 445 JAPAN: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 326 TABLE 446 JAPAN: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 327 TABLE 447 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 327 TABLE 448 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 328 TABLE 449 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 328 TABLE 450 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 329 TABLE 451 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 329 TABLE 452 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 329 TABLE 453 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 331 TABLE 454 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 331 TABLE 455 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 332 TABLE 456 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 332 TABLE 457 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 333 TABLE 458 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 333 TABLE 459 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 334 TABLE 460 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 334 TABLE 461 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 334 TABLE 462 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 336 TABLE 463 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 336 TABLE 464 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 337 TABLE 465 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 337 TABLE 466 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 338 TABLE 467 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 338 TABLE 468 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 339 TABLE 469 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 339 TABLE 470 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 339 TABLE 471 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 340 TABLE 472 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 341 TABLE 473 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 341 TABLE 474 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 341 TABLE 475 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 342 TABLE 476 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 342 TABLE 477 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 343 TABLE 478 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 343 TABLE 479 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 343 TABLE 480 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 344 TABLE 481 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 345 TABLE 482 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 345 TABLE 483 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 345 TABLE 484 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 346 TABLE 485 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 346 TABLE 486 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 347 TABLE 487 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 347 TABLE 488 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 347 TABLE 489 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 348 TABLE 490 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 349 TABLE 491 BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 349 TABLE 492 BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 350 TABLE 493 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 350 TABLE 494 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 351 TABLE 495 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 351 TABLE 496 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 352 TABLE 497 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 352 TABLE 498 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 352 TABLE 499 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 353 TABLE 500 MEXICO: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 354 TABLE 501 MEXICO: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 354 TABLE 502 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 354 TABLE 503 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 355 TABLE 504 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 355 TABLE 505 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 356 TABLE 506 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 356 TABLE 507 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 356 TABLE 508 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 357 TABLE 509 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 357 TABLE 510 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 358 TABLE 511 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 358 TABLE 512 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 359 TABLE 513 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 359 TABLE 514 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 360 TABLE 515 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 360 TABLE 516 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 360 TABLE 517 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 361 TABLE 518 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 361 TABLE 519 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 362 TABLE 520 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 362 TABLE 521 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 363 TABLE 522 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 363 TABLE 523 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 364 TABLE 524 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 364 TABLE 525 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 364 TABLE 526 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 365 TABLE 527 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 365 TABLE 528 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 366 TABLE 529 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 366 TABLE 530 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 366 TABLE 531 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 367 TABLE 532 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 367 TABLE 533 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 368 TABLE 534 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 368 TABLE 535 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 368 TABLE 536 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 369 TABLE 537 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 370 TABLE 538 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 370 TABLE 539 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 371 TABLE 540 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 371 TABLE 541 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 372 TABLE 542 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 372 TABLE 543 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 373 TABLE 544 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 373 TABLE 545 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 373 TABLE 546 UAE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 374 TABLE 547 UAE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 375 TABLE 548 UAE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 375 TABLE 549 UAE: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 375 TABLE 550 UAE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 376 TABLE 551 UAE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 376 TABLE 552 UAE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 377 TABLE 553 UAE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 377 TABLE 554 UAE: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 377 TABLE 555 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 378 TABLE 556 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 378 TABLE 557 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 379 TABLE 558 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 379 TABLE 559 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 380 TABLE 560 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 380 TABLE 561 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 381 TABLE 562 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 381 TABLE 563 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 381 TABLE 564 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 382 TABLE 565 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 383 TABLE 566 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 383 TABLE 567 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 383 TABLE 568 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 384 TABLE 569 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 384 TABLE 570 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 385 TABLE 571 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 385 TABLE 572 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 385 TABLE 573 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION) 386 TABLE 574 AFRICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 387 TABLE 575 AFRICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION) 387 TABLE 576 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION) 387 TABLE 577 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 388 TABLE 578 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION) 388 TABLE 579 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION) 389 TABLE 580 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION) 389 TABLE 581 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 389 TABLE 582 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SERVICES MARKET, JANUARY 2021–JANUARY 2025 390 TABLE 583 CLINICAL TRIAL SERVICES MARKET: DEGREE OF COMPETITION, 2024 395 TABLE 584 CLINICAL TRIAL SERVICES MARKET: REGION FOOTPRINT 399 TABLE 585 CLINICAL TRIAL SERVICES MARKET: SERVICE TYPE FOOTPRINT 400 TABLE 586 CLINICAL TRIAL SERVICES MARKET: PHASE FOOTPRINT 401 TABLE 587 CLINICAL TRIAL SERVICES MARKET: DETAILED LIST OF KEY STARTUP/SMES 404 TABLE 588 CLINICAL TRIAL SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 405 TABLE 589 CLINICAL TRIAL SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 408 TABLE 590 CLINICAL TRIAL SERVICES MARKET: DEALS, JANUARY 2021–JANUARY 2025 409 TABLE 591 CLINICAL TRIAL SERVICES MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025 410 TABLE 592 IQVIA INC.: COMPANY OVERVIEW 411 TABLE 593 IQVIA INC.: SERVICES OFFERED 412 TABLE 594 IQVIA INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 414 TABLE 595 IQVIA INC.: DEALS, JANUARY 2021–JANUARY 2025 414 TABLE 596 IQVIA INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 416 TABLE 597 ICON PLC: COMPANY OVERVIEW 418 TABLE 598 ICON PLC: SERVICES OFFERED 419 TABLE 599 ICON PLC: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 426 TABLE 600 ICON PLC: DEALS, JANUARY 2021–JANUARY 2025 426 TABLE 601 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 428 TABLE 602 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 429 TABLE 603 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 435 TABLE 604 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025 435 TABLE 605 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 437 TABLE 606 FORTREA: COMPANY OVERVIEW 439 TABLE 607 FORTREA: SERVICES OFFERED 440 TABLE 608 FORTREA: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 444 TABLE 609 FORTREA: DEALS, JANUARY 2021–JANUARY 2025 444 TABLE 610 FORTREA: EXPANSIONS, JANUARY 2021–JANUARY 2025 445 TABLE 611 SYNEOS HEALTH: COMPANY OVERVIEW 446 TABLE 612 SYNEOS HEALTH: SERVICES OFFERED 447 TABLE 613 SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 448 TABLE 614 SYNEOS HEALTH: DEALS, JANUARY 2021–JANUARY 2025 448 TABLE 615 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 453 TABLE 616 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED 455 TABLE 617 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 456 TABLE 618 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS, JANUARY 2021–JANUARY 2025 456 TABLE 619 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS, JANUARY 2021–JANUARY 2025 457 TABLE 620 MEDPACE: COMPANY OVERVIEW 459 TABLE 621 MEDPACE: SERVICES OFFERED 460 TABLE 622 WUXI APPTEC: COMPANY OVERVIEW 463 TABLE 623 WUXI APPTEC: SERVICES OFFERED 464 TABLE 624 WUXI APPTEC: DEALS, JANUARY 2021–JANUARY 2025 467 TABLE 625 FRONTAGE LABS: COMPANY OVERVIEW 468 TABLE 626 FRONTAGE LABS: SERVICES OFFERED 469 TABLE 627 FRONTAGE LABS: DEALS, JANUARY 2021–JANUARY 2025 470 TABLE 628 FRONTAGE LABS: EXPANSIONS, JANUARY 2021–JANUARY 2025 471 TABLE 629 PHARMARON: COMPANY OVERVIEW 472 TABLE 630 PHARMARON: SERVICES OFFERED 474 TABLE 631 TIGERMED: COMPANY OVERVIEW 475 TABLE 632 TIGERMED: SERVICES OFFERED 476 TABLE 633 TIGERMED: SERVICE APPROVALS, JANUARY 2021–JANUARY 2025 478 TABLE 634 TIGERMED: DEALS, JANUARY 2021–JANUARY 2025 479 TABLE 635 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW 480 TABLE 636 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: SERVICES OFFERED 482 TABLE 637 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 483 TABLE 638 EUROFINS SCIENTIFIC: SERVICES OFFERED 485 TABLE 639 LINICAL: COMPANY OVERVIEW 486 TABLE 640 LINICAL: SERVICES OFFERED 488 TABLE 641 LINICAL: DEALS, JANUARY 2021–JANUARY 2025 488 TABLE 642 LINICAL: EXPANSIONS, JANUARY 2021–JANUARY 2025 489 TABLE 643 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW 490 TABLE 644 PAREXEL INTERNATIONAL CORPORATION: SERVICES OFFERED 491 TABLE 645 PAREXEL INTERNATIONAL CORPORATION: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 492 TABLE 646 PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2021–JANUARY 2025 492 TABLE 647 PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025 494 TABLE 648 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW 495 TABLE 649 PROPHARMA: COMPANY OVERVIEW 497 TABLE 650 NOVOTECH: COMPANY OVERVIEW 498 TABLE 651 PSI: COMPANY OVERVIEW 501 TABLE 652 ALLUCENT: COMPANY OVERVIEW 502 TABLE 653 PREMIER RESEARCH: COMPANY OVERVIEW 503 TABLE 654 CAIDYA: COMPANY OVERVIEW 504 TABLE 655 ERGOMED GROUP: COMPANY OVERVIEW 505 TABLE 656 CLARIO: COMPANY OVERVIEW 507 TABLE 657 PRECISION MEDICINE GROUP, LLC: COMPANY OVERVIEW 508 TABLE 658 ADVANCED CLINICAL: COMPANY OVERVIEW 509 TABLE 659 EPS HOLDINGS, INC.: COMPANY OVERVIEW 510 TABLE 660 GUIRES INC. (PEPGRA): COMPANY OVERVIEW 511 TABLE 661 KCR S.A.: COMPANY OVERVIEW 512 FIGURE 1 CLINICAL TRIAL SERVICES MARKET: SEGMENTATION 46 FIGURE 2 CLINICAL TRIAL SERVICES MARKET: REGIONAL SCOPE 47 FIGURE 3 RESEARCH DESIGN 51 FIGURE 4 CLINICAL TRIAL SERVICES MARKET: BREAKDOWN OF PRIMARIES 53 FIGURE 5 GLOBAL MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024 55 FIGURE 6 ILLUSTRATIVE EXAMPLE OF IQVIA, INC.: REVENUE SHARE ANALYSIS (2024) 55 FIGURE 7 CLINICAL TRIAL SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 54 FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 56 FIGURE 9 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 57 FIGURE 10 CLINICAL TRIAL SERVICES MARKET: CAGR PROJECTIONS 58 FIGURE 11 DATA TRIANGULATION METHODOLOGY 60 FIGURE 12 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2025 VS. 2030 (USD MILLION) 63 FIGURE 13 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 64 FIGURE 14 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024 (USD MILLION) 65 FIGURE 15 CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024 (USD MILLION) 65 FIGURE 16 CLINICAL TRIAL SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 66 FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CLINICAL TRIAL SERVICES MARKET DURING FORECAST PERIOD 67 FIGURE 18 GROWING DEMAND FOR PEDIATRIC CLINICAL TRIALS FOR VARIOUS MARKETED DRUGS TO CREATE LUCRATIVE OPPORTUNITIES FOR MARKET PLAYERS 68 FIGURE 19 SMALL MOLECULES SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF NORTH AMERICAN CLINICAL TRIAL SERVICES MARKET IN 2024 69 FIGURE 20 CLINICAL TRIAL MANAGEMENT & MONITORING SEGMENT DOMINATED MARKET IN 2030 69 FIGURE 21 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT HELD LARGEST SHARE OF CLINICAL TRIAL SERVICES MARKET IN 2024 70 FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 70 FIGURE 23 DRIVERS, OPPORTUNITIES, AND CHALLENGES IN CLINICAL TRIAL SERVICES MARKET 71 FIGURE 24 R&D SPEND OF LARGE PHARMACEUTICAL COMPANIES, 2014–2023 (USD BILLION) 74 FIGURE 25 BIOSIMILAR APPROVALS IN US, 2015–2024 75 FIGURE 26 NUMBER OF CLINICAL TRIALS FOR VARIOUS MODALITIES 79 FIGURE 27 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS 82 FIGURE 28 CLINICAL TRIAL SERVICES MARKET: VALUE CHAIN ANALYSIS 85 FIGURE 30 CLINICAL TRIAL SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 104 FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES, BY END USER 106 FIGURE 32 KEY BUYING CRITERIA FOR CLINICAL TRIAL SERVICES, BY END USER 107 FIGURE 33 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021–2024 155 FIGURE 34 PHASE III CLINICAL TRIALS, 2014–2024 156 FIGURE 35 PHASE II CLINICAL TRIALS, 2014–2024 159 FIGURE 36 PHASE I CLINICAL TRIALS, 2014–2024 163 FIGURE 37 NUMBER OF REGISTERED ONCOLOGY CLINICAL TRIALS, 2012–2024 (THOUSAND) 183 FIGURE 38 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 194 FIGURE 39 GLOBAL R&D PIPELINE, 2015–2024 249 FIGURE 40 R&D SPENDING BY LARGE PHARMA COMPANIES, 2015–2023 (USD BILLION) 249 FIGURE 41 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET SNAPSHOT 261 FIGURE 42 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET SNAPSHOT 310 FIGURE 43 CLINICAL TRIALS IN JAPAN, 1999–2024 325 FIGURE 44 CLINICAL TRIAL SERVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION) 393 FIGURE 45 CLINICAL TRIAL SERVICES MARKET SHARE ANALYSIS, 2024 394 FIGURE 46 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 397 FIGURE 47 CLINICAL TRIAL SERVICES MARKET: COMPANY FOOTPRINT 398 FIGURE 48 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 403 FIGURE 49 CLINICAL TRIAL SERVICES MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 406 FIGURE 50 CLINICAL TRIAL SERVICES MARKET: EV/EBITDA OF KEY VENDORS, 2024 406 FIGURE 51 CLINICAL TRIAL SERVICES MARKET: BRAND/SERVICE COMPARISON 407 FIGURE 52 IQVIA INC.: COMPANY SNAPSHOT (2024) 412 FIGURE 53 ICON PLC: COMPANY SNAPSHOT (2023) 419 FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 429 FIGURE 55 FORTREA: COMPANY SNAPSHOT (2023) 440 FIGURE 56 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2023) 454 FIGURE 57 MEDPACE: COMPANY SNAPSHOT (2024) 460 FIGURE 58 WUXI APPTEC: COMPANY SNAPSHOT (2023) 464 FIGURE 59 FRONTAGE LABS: COMPANY SNAPSHOT (2023) 469 FIGURE 60 PHARMARON: COMPANY SNAPSHOT (2023) 473 FIGURE 61 TIGERMED: COMPANY SNAPSHOT (2023) 476 FIGURE 62 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2023) 481 FIGURE 63 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 484 FIGURE 64 LINICAL: COMPANY SNAPSHOT (2023) 487

同分類最新報告（包裝）

查看包裝全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們